Consent at Last

A working group including members of the Lacks family approves the first projects to use the HeLa genome.

Written byErin Weeks
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Henrietta Lacks in 1945WIKIMEDIA, IMAGE COURTESY OF THE LACKS FAMILY Four biomedical research groups have been approved by a National Institutes of Health (NIH) committee to access the HeLa genome under an agreement enacted with the help of the Lacks family in August. The cell line, established in 1951 from cervical cancer patient Henrietta Lacks, was the subject of controversy earlier this year when researchers published the HeLa genome without the consent of Lacks’s surviving family.

The HeLa Genome Data Access Working Group, which includes representatives of the Lacks family and from the NIH, was formed to ensure the HeLa genome would be used in projects consistent with the family’s wishes to preserve their privacy, as well as the cell line’s history of public good. Of six applicants to date, four projects were approved and two are pending, according to NIH.

Last month, when the HeLa genome agreement was reached, science journalist Rebecca Skloot told The Scientist: “What’s important is that this is a very big statement from the NIH and from the scientific community saying, ‘It matters to know what the subjects want and to tell them what’s going on.”’ In that way, yes, this is setting an important precedent.”

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies